The Efficacy of T-Bet in Intraocular Pressure Reduction in Patients with Primary Open Angle Glaucoma

Glaucoma

Abstract

Introduction: Glaucoma is the second most common cause of blindness and number one cause of irreversible deterioration of vision worldwide[1]. It affects approximately 70 million people and leads to irreversible blindness inapproximately 10% of those affected[2]. The only treatment that can effectively prevent the development and progression of glaucoma is reduction of intraocular pressure (IOP)[3,4]. Monotherapy is frequently insufficient for reaching the preset target IOP and thus the need for multitherapy[5]. When two drugs are required to control IOP, there are a number of potential advantages to using a fixed combination[4]. T-BET is a travoprost 0.004% – timolol 0.5% fixed combination

Aim: To report the efficacy of T-BET as a fixed combination prostaglandin-timolol anti-glaucoma medication in IOP reduction among primary open angle glaucoma patients at the University College Hospital, Ibadan.

Methods: Newly diagnosed patients with POAG were recruited in this study. A pre-commencement of T-BET IOP measurement was performed and a repeat IOP measurement was taken 3 weeks on T-BET use. All IOP were taken between the hours of 10am and 2pm. The inclusion criteria for this study included; Open angle glaucoma (POAG, NTG, JOAG), newly diagnosed or has not been on medications in the last 4 weeks. The exclusion criteria were; previous intraocular surgeries, previous laser procedure, decline enrolment.